INDEX 843
otitis media, 541–551
clinical features, 544,554–557
diagnostics, 546–548, 562
differential diagnosis, 544–545, 561
etiology/pathogenesis, 542
primary secretory, 541, 543, 544,554–555
sample collection, 31, 35
signalment/history, 543
therapeutics, 151, 548–551
Otobius megnini, 243
Otodectes cynotis,558,634, 641
clinical features, 635, 646
diagnostics, 43, 636
therapeutics, 637–638
otoscopy, 546
ototoxicity, 541, 551
otter hound, 740
outside-inside-outside theory, atopic disease, 173–174
Ovabanseemegestrol acetate
ovarian cysts/tumors, 339, 341, 345
oxacillin, 802
oxidizing agents,149, 150
oxymorphone, 802
oxytetracycline, 802
p53tumor suppressor gene, 494, 574, 615, 672, 711
pachyonychia, 588
paecilomycosis, 64
Pagetoid reticulosis, 366, 367, 377
pancreatic/hepatic paraneoplastic alopecia, felinesee
paraneoplastic alopecia, feline
pancreatic tumors
feline paraneoplastic alopecia, 616, 623
panniculitis, 565
superficial necrolytic dermatitis, 616, 665, 667,
671
Panectylseetrimeprazine
panepidermal pustular pemphigus/pemphigus
vegetans (PEP/Pveg)
clinical features, 191, 206
course and prognosis, 198
diagnostics, 194–195
differential diagnosis, 193
etiology/pathophysiology, 188
signalment/history, 189
therapeutics, 196
Panmycinseetetracycline
panniculitis, 563–566
clinical features,26,564,567–570
diagnostics, 565–566,571–573
mycobacterial, 511, 512, 513,519–520
pancreatic, 565
sterile (idiopathic) nodular (SNP), 65,126,563,
564, 565, 566
papillomatosis, 40
papillomaviruses, 711
canine,602,713,723–726
feline, 712
papillon, 740
papule, 13, 17
paraneoplastic alopecia, feline
(pancreatic/hepatic), 616
clinical features, 61,93,619–620,631–632
diagnostics, 623
differential diagnosis, 621
signalment/history, 617
therapeutics, 625
paraneoplastic dermatoses, 615–625
canine, 615–616
clinical features, 619,627–631
diagnostics, 621, 622
differential diagnosis, 620–621
signalment/history, 617
therapeutics, 623–624
feline, 616
clinical features, 619–620,631–633
diagnostics, 621, 623
differential diagnosis, 621
signalment/history, 617–618
therapeutics, 625
paraneoplastic pemphigus (PP)
clinical features, 191,206–207,619,629–630
course and prognosis, 198
diagnostics, 194–195, 622
differential diagnosis, 193, 621
etiology/pathophysiology, 188, 616
signalment/history, 189, 617
therapeutics, 196, 624
parasitic diseases
clawfold region, 66, 132
exfoliative dermatosis, 62, 95
keratinization defects, 435, 453
nodules and draining sinuses, 68
zoonotic, 727–728, 729
see alsomite infestations
paronychia, 588, 590
bacterial, 66,132,594, 601
clinical features, 590,601–604
dermatophytosis, 330
direct impression smears, 46
treatment, 593, 594
yeast/Malassezia, 589, 594, 601
paroxetine, 234, 803
pars flaccida, 542, 551
swelling, 544, 554
pars tensa, 542,551–552
Pasteurella multocida, 213
patches, 13, 19
Patnaik grading system, mast cell tumors, 497
pattern baldness, 60,79–80
Pautrier’s microabscess, 40
Paxilseeparoxetine
PBZseetripelennamine citrate
PCRseepolymerase chain reaction
pekingese, 339, 673, 740
Pelamineseetripelennamine citrate
pelodera, 64
Pembroke Welsh corgi, 740